Efficacy and Safety of Remibrutinib After Switching from Ocrelizumab in Participants with Relapsing Multiple Sclerosis, Followed by an Open Treatment with Remibrutinib
Summary description of the study
Remibrutinib is an investigational drug being developed for various diseases, including Relapsing Multiple Sclerosis (RMS). The purpose of this research project is to determine whether Remibrutinib could be a safe and effective alternative therapy for use after Ocrelizumab in the aging RMS population (40 years or older). This is an open-label clinical trial (participants and doctors are aware of the treatment the participants are receiving), in which participants will be treated for up to 48 months (4 years). This clinical trial includes a screening phase (up to 5 weeks), a treatment period (up to 4 years), and a safety follow-up period (4 weeks after study completion for eligible participants). The treatment period consists of two parts: the first part, referred to as the main part, and the second part, referred to as the extension part. During the main part, 50% of participants will receive Remibrutinib for up to 2 years, and 50% will receive Ocrelizumab for the same duration. During the extension part, all participants who are eligible to continue (completion of the two-year study treatment in the main part) and are interested in continuing the study will receive Remibrutinib for up to two years. After the completion of the open treatment, participants may require an additional 4-week safety follow-up period after their last dose in the study treatment. Approximately 360 individuals (men and women) aged 40 years or older, who have received an RMS diagnosis and meet specific eligibility criteria, may participate in this trial. Participants must have received Ocrelizumab for at least 18 months, and the last administration of Ocrelizumab must have occurred within 5 to 9 months prior to enrollment in the study.
(BASEC)
Intervention under investigation
Medication
The investigational drug is Remibrutinib, labeled as LOU064.
The comparator drug is Ocrelizumab.
For the first part of the study (main part), a computer program will be used to randomly assign each participant to one of the two study treatments (also referred to as randomization) for up to 2 years in this study:
• Remibrutinib is a film-coated tablet for oral administration.
• Ocrelizumab is administered as an intravenous infusion (injected into veins) or as a subcutaneous injection (under the skin), and is given every 6 months (at a dose of 600 mg/500 mL as an infusion or 920 mg/23 mL as an injection) according to clinical routine practice.
In the second part of the study (extension part), all participants who are eligible for the study (all participants who have completed the 24-month study treatment in the first part) and are interested in continuing the study will be treated with Remibrutinib for up to 2 years.
(BASEC)
Disease under investigation
Relapsing Multiple Sclerosis
(BASEC)
• Male or female, at least 40 years old at screening. • RMS diagnosis during the screening. • EDSS score of 0 to (including) 6.5 at screening and at randomization. • Treatment with Ocrelizumab according to clinical routine practice and standard dosing for at least 18 months. The last administration of Ocrelizumab must have occurred within 5 to 9 months prior to randomization. (BASEC)
Exclusion criteria
• Diagnosis of primary progressive multiple sclerosis (PPMS) during the screening. • History of clinically significant central nervous system (CNS) disease (e.g., stroke, traumatic brain or spinal cord injury, history or presence of myelopathy) or neurological diseases that may resemble MS during the screening. • History of confirmed progressive multifocal leukoencephalopathy (PML) or neurological symptoms that, prior to randomization, are consistent with PML. (BASEC)
Trial sites
Bern, Zurich
(BASEC)
Sponsor
Novartis Pharma AG
(BASEC)
Contact
Contact Person Switzerland
Marcela Unterspann
+41 79 711 64 71
marcela.unterspann@clutternovartis.comNovartis Pharma AG
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Zurich
(BASEC)
Date of authorisation
25.07.2025
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available